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than 0.05 was considered significant. RESULTS: Out of 1500 questionnaires, 1000
were received (response rate 0f 66.6%). Majority of the respondents were Libyans (n
 883; 88.3 %) while 117 (11.7%) were non Libyans. Fifty three percent (n474) of
Libyans respondents were females while seventy four percent (n87) of non Liby-
ans respondentsweremales. Forty eight per cents (n420) of Libyans and forty four
percent (n 51) of non Libyans were categorized in 25–40 years age group. Majority
(n529; 59.9%) of Libyans respondents had high level of education while non Lib-
yans respondents (n 61; 52.1) had intermediate education. Knowledge score was
significantly higher among Libyans (11.7  3.8) than non Libyans (9.7 4.7, t 
26.13), (P 0.001). A significant differencewasnotedwhen Libyans andnon Libyans
were compared with age, gender and tertiary educations level (P  0.001). No sig-
nificant differences were seen among other demographic variables and knowledge
scores. CONCLUSIONS: The present study findings showed that overall level of
knowledge of Libyans andnon Libyans respondentswas low; however, Libyans had
more knowledge than non Libyans about TB. There is a need of massive health
education campaign by policy makers in order to improve the population’s knowl-
edge towards TB.
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OBJECTIVES: The Clinical COPD Questionnaire (CCQ) was designed in Dutch and
UK English to measure health status in patients with COPD. Prior to use in an
international study including the Philippines and India, the instrument underwent
a linguistic validation. The objectives were: 1) to obtain English versions concep-
tually equivalent to the original and culturally relevant for use in the Philippines
and India, and 2) to determine if the development of specific English versions was
relevant. METHODS: The English versions for the Philippines and India were de-
veloped by a linguistic expert, and reviewed by the developer and a local clinician.
In each country, cognitive interviewswere performedwith five COPD patients. The
differences between the UK English original and adjusted English versions were
analyzed and coded as cultural, lexical, or syntactic. RESULTS: The two versions
showeddifferenceswhen compared to theUKEnglish: 14 for the English version for
India, and 12 for the English version for the Philippines. None of them were cul-
tural. In most cases the differences were lexical. For instance, in both countries,
“circle” in the original was replaced by “encircle,” “hardly ever” by “rarely,” “down”
by “sad.” “Washing yourself” was changed to “bathing yourself” (India) and “taking
a bath” (Philippines), “getting a cold” to “catching a cold” (India) and “getting colds”
(Philippines), “short of breath at rest” to “short of breath while at rest” (India) and
“short of breathwhile resting” (Philippines). All changeswere validated by patients;
somewere specifically requested by patients during the cognitive interviews as the
existing wording was considered confusing. CONCLUSIONS: The development of
the English versions for the Philippines and India confirms the importance of a
careful review and development of specific English versions for various English-
speaking countries, even for questionnaires which do not seem conceptually chal-
lenging at first glance.
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OBJECTIVES: In many countries a large portion of COPD patients are paying cash
for the most innovative medications. It is reasonable to believe that there is the
potential to respond to the medical need, and expected value of public payers vs.
self payers, by developing a newmolecule delivered in different inhalers for differ-
ent markets. This could be an interesting strategy for companies trying to maxi-
mise the level of access. Contrary to China and India, in markets with a single
payer, such as Korea, a price discrimination based on different inhalers would not
be reasonable. The objective of this study is to compare the effectiveness and
sustainability of a device based price discrimination strategy in the COPDmarket in
India (cashmarket), China (mixed system) and Korea (public coverage).METHODS:
Qualitative discussions with a representative sample of payers based on two prod-
uct profiles of the same molecule, delivered in two different devices: a high tech
multi dose DPI and a simplemonodose inhaler. RESULTS: Price discriminationwas
possible in India where the market is mainly cash but not in China or Korea. In
China, the existence on themarket of a low cost devicemakes the premium device
unattractive for the public payer at the regional level. In Korea, the launch of the
low cost inhaler would trigger a re-review of the premium inhaler by HIRA.
CONCLUSIONS: Companies find attractive the idea of discriminating the price
based on the level of health care coverage a patient has access to. However this
study demonstrates that discriminating the price of a product based on the target
patient segment is not only difficult in countries providing a universal health care
coverage, but also in those countries where there is a mixed cash/public system. It
is possible, howver, in cash markets such as India.
SENSORY SYSTEMS DISORDERS - Clinical Outcomes Studies
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OBJECTIVES: 1) Assessment of the periodontal status among 35-44 year old tobacco
users using Community Periodontal Index; 2) Estimation of Nicotine levels in Blood
and Urine by Spectrophotometry; and 3) Correlation between Nicotine levels in the
Blood and Urine samples of the subjects and their Periodontal status.METHODS:A
cross sectional institution based study was conducted to assess the periodontal
status of different tobacco users and the nicotine concentration in their blood and
urine. The study instrument consisted of a questionnaire for recording information
on tobacco use. The second part was for recording the clinical data using Commu-
nity Periodontal Index. The third partwas to record the concentration of nicotine in
blood and urine by spectrophotometry. Karl Pearson Chi-square test and Karl Pear-
son Correlation tests were used and data was analyzed using SPSS -17 software.
RESULTS: In this study of 150 male subjects aged between 35-44 years aimed at
assessing and comparing the periodontal status of tobacco users and non tobacco
users the findings showed tobacco userswith the highest prevalence of periodontal
disease. The difference in community periodontal index scores of various tobacco
users and non tobacco users was found to be statistically significant (p0.0005).
When blood and urine nicotine levels were compared with various forms of to-
bacco users, the nicotine levels was maximum in beedi smokers and minimum in
cigarette smokers. However, there was no significant correlationwhen periodontal
status was correlated with nicotine levels in blood and urine (p0.0005).
CONCLUSIONS: The findings suggested amarked association between tobacco use
and prevalence of periodontal disease. The present study showed that blood and
urine nicotine level is increased in various tobacco users compared to non tobacco
users. The nicotine levels in blood and urine may be considered as good indicators
to assess the exposure to tobacco in our population.
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OBJECTIVES: To investigate the epidemiology, treatment patterns and associated
medical expenses of diabeticmacular edema (DME).METHODS:Datawas collected
and analyzed from 1 January 2004 to 31 December 2009 from Taiwan National
Health Insurance Research Database, a source that covers more than 99% of Tai-
wan’s 23million citizens. Study subjectswere recorded as havingDME according to
ICD-9-CM codes. The 6-year trends in prevalence, treatment patterns and associ-
ated medical expenses of DME were retrieved and calculated from 2004 to 2009.
Age, gender and treatment distribution of treated DME visual impairment patients
were estimated in 2009. RESULTS: In 1.43million diabetesmellitus population, 0.11
million patients (7.3%) have DME and 18.6 thousand patients (1.3%) have received
treatment for DME visual impairment. The direct medical cost of DME patient was
3.1 times higher than the average national health expenditure per person (NTD
100,005 vs. NTD 32,240). Most treated DME visual impairment patients were older
than 50 years. Themale-to-female ratio was 1.05. There were 85.5% of treated DME
visual impairment patients receiving laser treatment. Among them, there were
73.6% laser only and 11.9% laser plus intravitreous injection (IVI) combination.
Average number of laser in current treatment pattern is three, and surgery (indi-
cator of deterioration) proportion remains high despite current treatment.
CONCLUSIONS: DME visual impairment patient population aligned with preva-
lence in other countries; 1.3% of DM patients treated with laser or IVI or vitrectomy
in Taiwan. Medical claims data have shown that un-licensed use of intravitreal
treatments in DME is increasing.
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OBJECTIVES:More than 40% of worldwide open-angle glaucoma (OAG) cases occur
in Asia. The OAG prevalence and associated economic burden are expected to rise
further.We extrapolated the findings from aGerman patient chart review in ocular
hypertension (OHT) and OAG to 10 Asia-Pacific countries using expert interviews,
in order to estimate the country specific OAG management costs.METHODS: Two
to 5 key opinion leaders per countrywere asked to reviewa list ofmedical resources
used in OHT/OAG (ophthalmologist visits, examinations/tests, outpatient or inpa-
tient surgery/laser, eye drops) collected during the retrospective COGIS study in 159
GermanOHT/OAGpatients, and approve the type and frequency of the resources or
modify them to represent their local practice. The amount of resources used was
presented by disease stage (OHT, early, moderate, advanced OAG) and number of
treatment changes (no change, 1, 2,3 changes) as the COGIS study demonstrated
an increased intensity of resource use depending on both parameters. Local unit
costs were collected and applied to each item to estimate the management costs
(All-payer perspective, 2011 costs). RESULTS: Thirty ophthalmologists validated
the data (Australia 2 experts, China 4, Hong Kong 3, India 5, Malaysia 3, New Zea-
land 3, South Korea 2, Singapore 2, Taiwan 2, Thailand 2). The increasing frequency
of resources used with increasing disease severity and number of switches was
generally approved. The average annual cost per patient ranged from 186US$ to
1689US$, mainly driven by topical medications, examinations/tests and clinical
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